2026 ICD-10-CM Diagnosis Code E85.89Other amyloidosis

ICD-10-CM Codes›E00–E89›E70-E88›E85

ICD-10-CM E85.89
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

E85.89 is a billable ICD-10-CM diagnosis code for other amyloidosis. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 545 through 547. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 10 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.

For Medicare Advantage risk adjustment, E85.89 maps to CMS-HCC Category 50 (Amyloidosis, Porphyria, and Other Specified Metabolic Disorders) under the V28 model, adding a risk factor of about 0.648 for a community, non-dual, aged beneficiary in payment year 2026.

Code Identity

ICD-10-CM Code
E85.89
Billable Status
Yes — Valid for Submission
Code Describes
Other amyloidosis
Short Description
Other amyloidosis
Same as the full description in the CMS dataset.
Parent Code
E85.8
Other amyloidosis

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE70-E88Metabolic disorders
CategoryE85Amyloidosis
This CodeE85.89Other amyloidosis

Medicare Risk Adjustment (HCC)Billing

E85.89 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.

CMS-HCC V28 Category (Payment Model)
HCC 50— Amyloidosis, Porphyria, and Other Specified Metabolic Disorders
Payment HCC · PY 2026 one of 32 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.648
community, non-dual, aged · ranges 0.362–0.883 across segments
Hierarchy
Top of its hierarchy
HCC 50 is not superseded by any other condition category
Prior Model (CMS-HCC V24)
HCC 23
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 23 · ESRD (V21): HCC 23 · ESRD (V24): HCC 23
ESRD V21 weights: 0.013 dialysis, 0.234–0.359 functioning graft · ESRD V24 weights: 0.036 dialysis, 0.217–0.390 functioning graft
Part D (RxHCC)
Not mapped
E85.89 does not risk-adjust in the RxHCC prescription drug model

Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • AA amyloid nephropathy
  • AA amyloidosis
  • Age-related amyloidosis
  • AH amyloidosis
  • AL amyloidosis
  • ALECT2 amyloidosis
  • Amyloid light chain amyloidosis due to multiple myeloma
  • Amyloid myopathy
  • Amyloid nephropathy
  • Apolipoprotein A-IV amyloidosis
  • Cerebral amyloid angiopathy
  • Cerebral amyloid angiopathy associated with systemic amyloidosis
  • Light chain disease
  • Myeloma-associated amyloidosis
  • Primary sporadic amyloid myopathy
  • Primary systemic amyloidosis associated with occult plasma cell dyscrasia
  • Pseudoscleroderma due to amyloid light-chain amyloidosis
  • Scleroderma-like secondary cutaneous sclerosis
  • Secondary systemic amyloidosis
  • Sporadic primary amyloidosis
  • Systemic amyloidosis
  • Systemic amyloidosis affecting skin

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END016
Other specified and unspecified nutritional and metabolic disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Amyloid Neuropathies, Familial

    inherited disorders of the peripheral nervous system associated with the deposition of amyloid in nerve tissue. the different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin (prealbumin); apolipoprotein a-i; and gelsolin.

  • Amyloidosis

    a group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of amyloid. as the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. various signs and symptoms depend on the location and size of the deposits.

  • Amyloidosis, Familial

    diseases in which there is a familial pattern of amyloidosis.

  • Cerebral Amyloid Angiopathy, Familial

    a familial disorder marked by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges.

  • Immunoglobulin Light-chain Amyloidosis

    a nonproliferative disorder of plasma cells characterized by excessive production and misfolding of immunoglobulin light chains that form insoluble amyloid fibrils (see amyloid deposits) in various tissues. clinical features include liver failure; multiple myeloma; nephrotic syndrome; restrictive cardiomyopathy, and neuropathies.

  • Cerebral Amyloid Angiopathy

    a heterogeneous group of sporadic or familial disorders characterized by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges. clinical features include multiple, small lobar cerebral hemorrhage; cerebral ischemia (brain ischemia); and cerebral infarction. cerebral amyloid angiopathy is unrelated to generalized amyloidosis. amyloidogenic peptides in this condition are nearly always the same ones found in alzheimer disease. (from kumar: robbins and cotran: pathologic basis of disease, 7th ed., 2005)

  • Amyloid

    a fibrous protein complex that consists of proteins folded into a specific cross beta-pleated sheet structure. this fibrillar structure has been found as an alternative folding pattern for a variety of functional proteins. deposits of amyloid in the form of amyloid plaques are associated with a variety of degenerative diseases. the amyloid structure has also been found in a number of functional proteins that are unrelated to disease.

  • AH Amyloidosis

    a rare type of amyloidosis characterized by the monoclonal deposition of immunoglobulin heavy chain fragments in organs and tissues. it is associated with plasma cell or b-cell lymphoproliferative disorders.

  • Cerebral Amyloid Angiopathy

    a disorder characterized by the deposition of amyloid in the wall of the vessels in the brain.

  • Cerebral Amyloid Angiopathy, APP-Related|HCHWAD|Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch Type

    an autosomal dominant form of cerebral amyloid angiopathy caused by mutation(s) in the app gene, encoding amyloid-beta a4 protein. the deposition of amyloid in cerebral blood vessels wall may lead to degenerative vascular changes that may result in cerebral hemorrhage. mutation(s) in the app gene may also cause autosomal dominant alzheimer disease 1.

Patient EducationClinical

Amyloidosis

Amyloidosis occurs when abnormal proteins called amyloids build up and form deposits. The deposits can collect in organs such as the kidney and heart. This can cause the organs to become stiff and unable to work the way they should.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert E85.89 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
277.39 Amyloidosis NEC
Approximate The match is approximate rather than exact.

Code History & ChangesHistory

Replacement E85.89 replaces the following previously assigned code(s):

  • E85.8 - Other amyloidosis
FY 2019AddedAdded to the ICD-10-CM code setEffective October 1, 2018.
FY 2020–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About E85.89Overview

What is the ICD-10 code for other amyloidosis?

The ICD-10-CM code for other amyloidosis is E85.89 (sometimes written as E8589). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is E85.89 (Other amyloidosis) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report other amyloidosis on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does E85.89 group to?

When other amyloidosis is the principal diagnosis on an inpatient stay, it groups to MS-DRG 545, 546, 547, with relative weights from 0.8362 to 2.4817 depending on complications. Higher weights mean higher Medicare reimbursement.

Is E85.89 a CC or MCC?

CMS lists E85.89 as a CC (complication or comorbidity) for FY 2026. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 10 closely related codes in its exclusion list.

What is the ICD-9 equivalent of E85.89?

Under the General Equivalence Mappings, other amyloidosis converts to ICD-9-CM 277.39 (amyloidosis NEC). The mapping is approximate, so confirm the match fits the documentation.

What HCC is E85.89?

E85.89 (other amyloidosis) maps to CMS-HCC Category 50 (Amyloidosis, Porphyria, and Other Specified Metabolic Disorders), commonly written as HCC 50, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 23 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.

Does E85.89 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, E85.89 adds a risk adjustment factor of about 0.648 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.362 to 0.883 depending on the payment segment). HCC 50 sits at the top of its hierarchy, so no other condition category supersedes it. See the full factor table on the HCC 50 category page.